Inflammation in Atherosclerosis: Thirty Years of Exploration in Basic and Clinical Science
presented by Texas Heart Institute and Brigham & Women's Hospital
Friday & Saturday, February 23-24, 2007 Boston, Massachusetts Online registration is now closed. Registration will be availble at the event.
Overview
Our knowledge of atherosclerosis has undergone a radical transformation in the past 30 years. Originally considered a bland accretion of lipids accompanied by a proliferation of smooth muscle cells, atherosclerosis is now widely recognized as an arterial disease with an inflammatory nature. The clarification of the role that inflammation plays in atherosclerosis helps us to understand how multiple risk factors, ranging from hypertension, dyslipidemia, diabetes, and smoking to aging, initiate and promote the progress of atherosclerotic plaques. Insights gained into the multifactorial etiology of atherosclerosis as an inflammatory disease have led to the development of novel strategies for the prevention and treatment of this disease. New discoveries of anti-inflammatory medicines enable physicians to target modalities directed at preventing its dreaded consequences—acute vascular syndromes. This symposium aims to link cutting-edge laboratory research with evolving clinical translation. Faculty will emphasize the basic mechanism as well as clinical problems frequently encountered by today’s cardiologist.
The intended audience includes physicians with an interest in the prevention and treatment of atherosclerosis; physicians and scientists engaged in basic and clinical research of atherosclerosis; and professionals of the biotechnology and medical industry.
Learning Objectives
At the conclusion of this symposium, participants will have gained significant knowledge in the following areas –
Pathophysiology of atherosclerosis and the biomarkers of inflammation.
Role of inflammation in plaque fissuring/rupture and thrombosis in acute coronary syndromes.
Comparison of various therapeutic approaches in acute coronary syndromes.
Benefit of anti-inflammatory therapies in combination with newer antiplatelet and antithrombotic agents in acute coronary syndromes.
Evaluation and management of established and emerging coronary risk factors.
Appropriate selection of diagnostic tests in evaluation of cardiac patients.
Role of aggressive lipid-lowering therapy for primary and secondary prevention.
Controversies and new therapies for management of high-risk patients.
Evaluation and management of cardiac disorders in patients with highly inflammatory, rupture-prone plaques.
Review of various established practice guidelines for cardiovascular disorders.
Program Directors
Yong-Jian Geng, MD, PhD—Texas Heart Institute
Peter Libby, MD—Brigham & Women's Hospital
Paul M. Ridker, MD—Brigham & Women's Hospital
James T. Willerson, MD—Texas Heart Institute
Schedule
Friday, February 23 7:00 a.m. through 4:45 p.m.
Dinner program—Harvard Club at 374 Commonwealth Avenue 6:15 p.m. through 9:00 p.m.
Saturday, February 24 8:00 a.m. through 12:30 p.m.
For schedule and faculty details, see the program brochure (PDF).
Accreditation
Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Texas Heart Institute designates this educational activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Registration fee includes all course materials, continental breakfasts, lunch, refreshment breaks, and Friday evening’s dinner.
$199 Physicians Registration $229 Industry Representatives Registration $79 Fellows and Residents Registration* $79 Allied Health Professionals Registration * Fellows-in-training and residents must provide a statement from their program directors regarding their status.
Online registration is now closed. Registration will be available at the event.
